Cargando…

EPH174 Adverse Events Associated with COVID-19 and Seasonal Influenza Vaccines: A Retrospective and Descriptive Analysis of CDC/FDA Vaccine Adverse Event Reporting System (VAERS) Reports

Detalles Bibliográficos
Autores principales:	Alqahtani, Z, Guo, JJ, Wigle, PR
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232792/ http://dx.doi.org/10.1016/j.jval.2022.04.925

Ejemplares similares

Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports
por: Riad, Abanoub, et al.
Publicado: (2022)

The temporal relationship between RotaTeq immunization and intussusception adverse events in the Vaccine Adverse Event Reporting System (VAERS)
por: Geier, David A., et al.
Publicado: (2012)

EPH106 Comparison of the Post-Marketing Safety Profile between Influenza and COVID-19 Vaccines: An Analysis of the Vaccine Adverse Event Reporting System (VAERS)
por: Alahmari, AK, et al.
Publicado: (2022)

Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics’ impact
por: Almadani, Ohoud A., et al.
Publicado: (2022)

Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case–control assessment of the vaccine adverse event reporting system (VAERS) database
por: Geier, David A., et al.
Publicado: (2016)

Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports
por: Guo, Wenxin, et al.
Publicado: (2022)

COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS)
por: Zhang, Bing, et al.
Publicado: (2022)

WITHDRAWN: A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products
por: Rose, Jessica, et al.
Publicado: (2021)

EPH139 COVID-19 Vaccine Related Adverse Events in a Population Aged 5–17 Years: A Study of Reports from the VAERS Database
por: Lee, Y, et al.
Publicado: (2022)

Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 – October 2021
por: Moro, Pedro L., et al.
Publicado: (2022)

Adverse event detection by integrating twitter data and VAERS
por: Wang, Junxiang, et al.
Publicado: (2018)

Ontology-based time information representation of vaccine adverse events in VAERS for temporal analysis
por: Tao, Cui, et al.
Publicado: (2012)

Identification of sex-associated network patterns in Vaccine-Adverse Event Association Network in VAERS
por: Zhang, Yuji, et al.
Publicado: (2015)

Linked vaccine adverse event data from VAERS for biomedical data analysis and longitudinal studies
por: Tao, Cui, et al.
Publicado: (2014)

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)
por: Welsh, Kerry J., et al.
Publicado: (2021)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990–2010
por: Goldman, GS, et al.
Publicado: (2012)

Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015
por: Moro, Pedro L., et al.
Publicado: (2016)

Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database
por: Falotico, Julianne M., et al.
Publicado: (2022)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021–June 30, 2022
por: Moro, Pedro L., et al.
Publicado: (2023)

Trivalent Influenza Vaccine Adverse Event Analysis Based On MedDRA System Organ Classes Using VAERS Data
por: Tao, Cui, et al.
Publicado: (2015)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

COVID-19 vaccine adverse events in a population aged 5–17 years: a study from the VAERS database
por: Villa-Zapata, Lorenzo, et al.
Publicado: (2023)

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
por: Iarikov, Dmitri, et al.
Publicado: (2015)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
por: Fukuda, Akiho, et al.
Publicado: (2017)

Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
por: Jiao, Xue-feng, et al.
Publicado: (2020)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

2463. Post-licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014–2017
por: Arana, Jorge, et al.
Publicado: (2018)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System
por: Jeon, Minji, et al.
Publicado: (2021)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
por: Li, Ying, et al.
Publicado: (2020)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013−May 31, 2015
por: Haber, Penina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0f2lisfn9iga1v3gs7ep7l1ssr